Global Etanercept Market Size To Reach USD 20.8 Billion By 2028

26-Apr-2022 | Facts and Factors

According to the Facts & Factors report, the global etanercept market was worth about 15.5 (USD billion) in 2021 and is predicted to grow to around 20.8 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 3.3%.

Etanercept is a biopharmaceutical anti-Tumor Necrosis Factor (TNF) agent used to treat autoimmune diseases like spondylitis and arthritis. TNF overproduction in the body causes pain, inflammation, and bone & joint damage. Etanercept inhibits TNF action and thus reduces inflammation. It's used to treat rheumatoid arthritis, juvenile rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Request Sample Request Customization Buy Now

Browse the full “Etanercept Market By Application (Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Others), By Distribution Network (Online and Offline), and By Region-Global and Regional Industry Trends, Competitive Intelligence, Analysis of Data, Statistical Data, and Forecast 2022-2028" report at https://www.fnfresearch.com/etanercept-market

During the forecast period, the global etanercept market is expected to grow at a rapid pace. This is due to an increase in the prevalence of lifestyle disorders, obesity, accidents, and spondylitis. When compared to certain other therapeutic proteins, Enbrel has seen a significant increase in demand. It is used to treat auto-immune diseases like psoriasis, juvenile rheumatoid arthritis, and plaque. The higher incidence of these diseases is estimated to propel the etanercept market. Furthermore, technological advancements and R & D activities may introduce new opportunities in the global market. However, rising overall treatment costs, the absence of reimbursement policies in developing nations, and treatment side effects are expected to restrain the global market.

The global etanercept market is segregated on the basis of application, distribution network, and region. By application, the market is divided into juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and others. In the year 2021, rheumatoid arthritis held a commanding market share. It is due to the high prevalence of osteoarthritis in different regions around the world. By distribution network, the market is divided into online and offline. In 2021, the offline segment held a commanding market share. It is due to reimbursement policies and the increasing adoption of AI as a supplement to a simple purchase.

North America's market is expected to expand rapidly in the coming years. The region's dominance in the global etanercept market is due to favorable reimbursement scenarios, acceptance of advanced techniques, and a technically sophisticated health care system. Etanercept's other major markets are Europe and the Asia Pacific. The presence of key players, increased investments in R&D activities by major pharma players, and collaborative partnerships between pharma & biotech companies and research institutes drive the etanercept market in these regions.

Report Scope

Report Attribute

Details

Market Size in 2021

USD 15.5 Billion

Projected Market Size in 2028

USD 20.8 Billion

CAGR Growth Rate

3.3% CAGR

Base Year

2021

Forecast Years

2022-2028

Key Market Players

GlaxoSmithKline, Novartis, Takeda, Clover Biopharmaceuticals, Johnson & Johnson, Roche, Celltrion, Pfizer, Cipla, and Samsung Bioepis, among others

Key Segment

By Application, Distribution Network, and Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

Some of the main competitors dominating the global etanercept market are GlaxoSmithKline, Novartis, Takeda, Clover Biopharmaceuticals, Johnson & Johnson, Roche, Celltrion, Pfizer, Cipla, and Samsung Bioepis.

Recent Development

  • December 2019: Clover Biopharma has begun Phase III studies in China for the Etanercept Biosimilar Candidate SCB-808. The first patient was given an injection of the biosimilar being developed in the preloaded syringe composition for the treatment of rheumatic diseases such as ankylosing spondylitis and rheumatoid arthritis, according to the company. The purpose of this study is to compare the efficacy, safety, and pharmacokinetics of SCB-808 and the originator drug Enbrel® in patients with ankylosing spondylitis after subcutaneous administration. 
  • November 2019: Samsung Bioepis and Biogen have announced a major commercialization agreement for two biosimilar applicants. The agreement gives Biogen the option to renew the commercialization term for Samsung Bioepis' three anti-TNF biosimilars – BENEPALI (etanercept), IMRALDI (adalimumab), and FLIXAB (infliximab) – in Europe for an additional five years, bringing the original ten-year agreement to a total of fifteen years. In Germany, France, Spain, Italy, and the United Kingdom, BENEPALI is the most commonly prescribed etanercept (UK). In Europe, IMRALDI is the leading adalimumab biosimilar. The agreement also gives Biogen the option of getting commercialization rights to BENEPALITM, FLIXABITM, and IMRALDITM in China in exchange for market royalties.

The global etanercept market is segmented as follows:

By Application

  • Juvenile Idiopathic Arthritis
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Others

By Distribution Network

  • Online
  • Offline

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Nordic countries
      • Denmark
      • Finland
      • Iceland
      • Sweden
      • Norway
    • Benelux Reunion
      • Belgium
      • The Netherlands
      • Luxembourg
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • New Zealand
    • Australia
    • South Korea
    • Southeast Asia
      • Indonesia
      • Thailand
      • Malaysia
      • Singapore
      • Rest of Southeast Asia
    • Rest of Asia Pacific
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Kuwait
    • South Africa
    • Rest of the Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:
Facts & Factors

A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com


Latest Market Research Reports

report img

Online On-Demand Laundry Service Market Report 2024 – 2032

[228+ Pages Report] According to Facts Factors, the global online on-demand laundry service market size in terms of revenue was valued at around USD 27.52 billion in 2023 and is expected to reach a value of USD 326.18 billion by 2032, growing at a CAGR of roughly 31.6% from 2024 to 2032. The global

Published Date : 27-May-2024 | | Category : Consumer Goods | Pages : 227 | Format : Read more

Inquiry for Buying Request Sample
report img

Portable Generator Market Report 2024 – 2032

[227+ Pages Report] According to Facts Factors, the global portable generator market size in terms of revenue was valued at around USD 4.87 billion in 2023 and is expected to reach a value of USD 8.12 billion by 2032, growing at a CAGR of roughly 5.84% from 2024 to 2032. The global portable generat

Published Date : 27-May-2024 | | Category : Energy & Mining | Pages : 228 | Format : Read more

Inquiry for Buying Request Sample
report img

Bubble Tea Market Report 2024 – 2032

[224+ Pages Report] According to Facts Factors, the global bubble tea market size in terms of revenue was valued at around USD 2,890 million in 2023 and is expected to reach a value of USD 6,120 million by 2032, growing at a CAGR of roughly 8.69% from 2024 to 2032. The global bubble tea market is p

Published Date : 24-May-2024 | | Category : Food & Beverages | Pages : 224 | Format : Read more

Inquiry for Buying Request Sample
report img

Greenhouse Horticulture Market Report 2024 – 2032

[224+ Pages Report] According to Facts Factors, the global greenhouse horticulture market size in terms of revenue was valued at around USD 32.16 billion in 2023 and is expected to reach a value of USD 64.38 billion by 2032, growing at a CAGR of roughly 8.02% from 2024 to 2032. The global greenhous

Published Date : 24-May-2024 | | Category : Energy & Mining | Pages : 224 | Format : Read more

Inquiry for Buying Request Sample
report img

E-Cigarette and Vape Market Report 2024 – 2032

[225+ Pages Report] According to Facts Factors, the global e-cigarette and vape market size in terms of revenue was valued at around USD 27.92 billion in 2023 and is expected to reach a value of USD 72.36 billion by 2032, growing at a CAGR of roughly 11.16% from 2024 to 2032. The global e-cigarette

Published Date : 24-May-2024 | | Category : Consumer Goods | Pages : 225 | Format : Read more

Inquiry for Buying Request Sample

Why FnF Market Research?

1 Inflallible Methodology

to ensure high-level data integrity, accurate analysis, and impeccable forecasts

2 Analyst Support

for complete satisfaction

3 Customization

on-demand customization of scope of the report to exactly meet your needs

4 Targeted Market View

Targeted market view to provide pertinent information and save time of readers

5 Agile Approach

A faster and efficient way to cater to the needs with continuous iteration